骨髓增生异常综合征预后因素研究新进展  

New Advance of Research on Prognostic Factors in Myelodysplastic Syndrome——Review

作　　者：隗佳[1,2] 陈燕[1] 

机构地区：[1]华中科技大学同济医学院协和医院血液病研究所,湖北武汉430022 [2]武汉同济医院

出　　处：《中国实验血液学杂志》2008年第6期1465-1472,共8页Journal of Experimental Hematology

摘　　要：骨髓增生异常综合征(MDS)是一组恶性克隆性干/祖细胞性疾病,其主要特征为无效造血所致的难治性血细胞减少和极易发展为急性白血病。研究认为MDS的预后受多种因素的影响,个体差异很大。随着WHO分型及各种新的积分系统在MDS预后判断中的应用、细胞遗传学及流式细胞技术的发展和各种新药的产生,不同类型MDS预后也在不断的变化,对MDS预后的判断也变得越来越客观。本文对影响MDS不同预后因素的近年来相关文献进行综述。在综述中讨论的问题包括有MDS分型存在的问题,预后积分系统与MDS,细胞遗传学与MDS预后,免疫表型特征以及治疗等与MDS预后的关系。Myelodysplastic syndrome（ MDS ） represents a heterogeneous group of myeloid malignancies characterized by abnormal differentiation and maturation of myeloid cells, bone marrow failure, and a genetic instability with enhanced risk to transform to acute myeloid leukemia. Many factors influence on the prognosis of MDS. The prognosis of MDS subtypes has been changing with the application of World Health Organization（WHO） classification and different new prognostic scoring system, the technology development of cytogenetics and flow cytometry, and the advent of new drugs. A series of recent literatures are summarized on different prognostic factors of MDS. In this review, the controversy in application of WHO classification, MDS prognosis in relation with prognostic scoring system, cytogenetics, immunophenotype and therapeutics were discussed.

关 键 词：骨髓增生异常综合征 预后因素 WHO分型 WPSS 细胞遗传学 免疫表型 

分 类 号：R733.7[医药卫生—肿瘤] R733.3[医药卫生—临床医学]